Glenmark Pharmaceuticals unlocks the treatment for mild to moderate Covid-19 in India
MUMBAI: In a landmark development for COVID-19 patients in India, Glenmark Pharmaceuticals announced the launch of antiviral drug Favipiravir (brand name FabiFlu) for the treatment of mild to moderate COVID-19 patients. Glenmark has received manufacturing and marketing approval from India’s…